HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amarin's Omega-3 Fair Trade Complaint Reaches Regulatory Dead End

This article was originally published in The Rose Sheet

Executive Summary

International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.

You may also be interested in...



Supreme Court Cosmetic, Food Decisions Shape Amarin's Appeal For Omega-3 Trade Inquiry

Amarin's petition to the Federal Circuit Court to direct ITC to investigate its complaint that some omega-3 ingredients are unapproved drugs leans on Supreme Court decisions that compliance with FDA regulations in cosmetic and food labeling does not preclude litigation alleging the information rendered a product an unapproved drug or represented false advertising.

SARMs Spells Latest 'Synthetic Steroids' FDA Finds In Supplements

FDA warns three US firms marketing products labeled as dietary supplements but containing selective androgen receptor modulators, SARMs, anabolic steroid-like ingredients that have the potential to increase the risk of heart attack and stroke and for which long-term effects are unknown.

Omega-3 Ingredients Fair Trade Complaint? Not FDA's Bailiwick, Amarin Says

The drug maker says it's not asking ITC to interpret the FD&C Act, but to investigate whether some omega-3 ingredient suppliers and marketers are failing to fulfill "certain marketplace expectations about the nature" of their products. ITC on Oct. 27 will vote on whether to investigate the complaint targeting a large part of the omega-3 market.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS121287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel